Division of Thoracic Oncology, Shizuoka Cancer Center, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Division of Rehabilitation Medicine, 1007, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
BMC Cancer. 2017 Aug 25;17(1):571. doi: 10.1186/s12885-017-3562-4.
Elderly patient with advanced cancer is one of the most vulnerable populations. Skeletal muscle depletion during chemotherapy may have substantial impact on their physical function. However, there is little information about a direct relationship between quantity of muscle and physical function. We sought to explore the quantitative association between skeletal muscle depletion, and muscle strength and walking capacity in elderly patients with advanced non-small cell lung cancer (NSCLC).
Thirty patients aged ≥70 years with advanced NSCLC (stage III-IV) scheduled to initiate first-line chemotherapy were prospectively enrolled between January 2013 and November 2014. Lumbar skeletal muscle index (LSMI, cm/m), incremental shuttle walking distance (ISWD, m), and hand-grip strength (HGS, kg) were assessed at baseline, and 6 ± 2 weeks (T2) and 12 ± 4 weeks (T3) after study enrollment. Associations were analyzed using linear regression.
Altogether, 11 women and 19 men with a median age of 74 (range, 70-82) years were included in the study; 24 received cytotoxic chemotherapy and 6, gefitinib. Mean ± standard deviation of LSMI, ISWD and HGS were 41.2 ± 7.8 cm/m, 326.0 ± 127.9 m, and 29.3 ± 8.5 kg, respectively. LSMI and ISWD significantly declined from baseline to T2 and T3. HGS significantly declined from baseline to T2 and T3 only in men. Change in LSMI was significantly associated with change in HGS (β = 0.3 ± 0.1, p = 0.0127) and ISWD (β = 8.8 ± 2.4, p = 0.0005).
Skeletal muscle depletion accompanied with physical functional decline started in the early phase of the chemotherapy in elderly patients with advanced NSCLC. Our results suggest that there may be a need for early supportive care in these patients to prevent functional decline during chemotherapy.
Trial registration number: UMIN000009768 Name of registry: UMIN (University hospital Medical Information Network). URL of registry: Date of registration: 14 January 2013. Date of enrolment of the first participant to the trial: 23 January 2013.
老年晚期癌症患者是最脆弱的人群之一。化疗期间骨骼肌耗竭可能对其身体功能产生重大影响。然而,关于肌肉量与身体功能之间直接关系的信息很少。我们旨在探讨老年晚期非小细胞肺癌(NSCLC)患者骨骼肌耗竭与肌肉力量和步行能力之间的定量关系。
2013 年 1 月至 2014 年 11 月期间,前瞻性纳入 30 名年龄≥70 岁、拟接受一线化疗的晚期 NSCLC(III-IV 期)患者。基线时、入组后 6±2 周(T2)和 12±4 周(T3)评估腰椎骨骼肌指数(LSMI,cm/m)、递增穿梭步行距离(ISWD,m)和握力(HGS,kg)。使用线性回归分析相关性。
共有 11 名女性和 19 名男性患者,中位年龄为 74 岁(范围,70-82 岁),24 名患者接受细胞毒性化疗,6 名患者接受吉非替尼治疗。LSMI、ISWD 和 HGS 的平均值±标准差分别为 41.2±7.8cm/m、326.0±127.9m 和 29.3±8.5kg。LSMI 和 ISWD 从基线至 T2 和 T3 显著下降。HGS 仅在男性中从基线到 T2 和 T3 显著下降。LSMI 的变化与 HGS(β=0.3±0.1,p=0.0127)和 ISWD(β=8.8±2.4,p=0.0005)的变化显著相关。
老年晚期 NSCLC 患者化疗早期即出现骨骼肌耗竭伴身体功能下降。我们的结果表明,这些患者可能需要早期支持性护理,以防止化疗期间的功能下降。
注册号:UMIN000009768 注册名称:UMIN(大学医院医学信息网络)。注册网址:注册日期:2013 年 1 月 14 日。试验首例参与者入组日期:2013 年 1 月 23 日。